IRStrategy
Pre-IPO - IR Infrastructure and Outreach
National, Clinical, Public
LHS needed to build IR credibility and visibility for TFF Pharmaceuticals, a Nasdaq company with a first-of-its-kind technology for inhalable therapeutics to solve a major drug delivery challenge. LHS supported TFF’s efforts to leverage its disruptive technology with commercial industry and governmental partnerships. In addition, LHS functioned as an external IR department, handling all aspects of investor relations and corporate communications.
LHS Solution
- Implement LHS Immersion® and BluePrint Planning process to discover differentiated messages and set the corporate visibility strategy for the Company
- Develop a “full charge” IR infrastructure program based on best practices to ensure disclosure, transparency and investor confidence
- Utilize LHS Reach™ to aggressively extend TFF’s outreach within the institutional investment community – both those who participated in the IPO, and other new names to the story
- Leverage LHS’ extensive capital markets access contact to introduce management to key analysts and bankers
Results
- Increased awareness and understanding of company’s value proposition
- Developed new corporate communications assets including a corporate profile video and investor presentation
- Created and distributed 20 corporate and financial disclosure releases in the span of just three months
- Coordinated more than 50 initial high-value one-on-one meetings with investors and potential business partners
- Arranged high visibility broadcast interviews with key reporters to further the profile of TFF’s leadership team
- Secured high profile institutional analyst coverage within three months, as well as numerous banking conference invitations
